HEPATOLOGÍA EXPERIMENTAL Y VECTORIZACIÓN DE FÁRMACOS
HEVEFARM
University of Padua
Padua, ItaliaPublicaciones en colaboración con investigadores/as de University of Padua (11)
2024
-
SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer
Cell Reports, Vol. 43, Núm. 3
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
2022
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
-
Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems
Seminars in Liver Disease, Vol. 42, Núm. 1, pp. 087-103
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
2021
-
Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System
Hepatology, Vol. 73, Núm. 6, pp. 2311-2325
-
REPLY:
Hepatology
-
REPLY:
Hepatology
-
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Expert Opinion on Investigational Drugs, Vol. 30, Núm. 4, pp. 377-388
2020
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
2019
-
Diagnostic and prognostic biomarkers in cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 108-122